# CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

> **NCT07096453** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Minnesota** · enrollment: 30 (estimated)

## Conditions studied

- Kidney Transplant; Complications
- CMV

## Interventions

- **DRUG:** Cytogam

## Key facts

- **NCT ID:** NCT07096453
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-02
- **Primary completion:** 2027-08
- **Final completion:** 2027-08
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07096453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07096453, "CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07096453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*